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Abstract
Aneuploidy is the leading cause of miscarriage and congenital birth
defects, and a hallmark of cancer. Despite this strong association
with human disease, the genetic causes of aneuploidy remain
largely unknown. Through exome sequencing of patients with
constitutional mosaic aneuploidy, we identified biallelic truncating
mutations in CENATAC (CCDC84). We show that CENATAC is a novel
component of the minor (U12-dependent) spliceosome that
promotes splicing of a specific, rare minor intron subtype. This
subtype is characterized by AT-AN splice sites and relatively high
basal levels of intron retention. CENATAC depletion or expression
of disease mutants resulted in excessive retention of AT-AN minor
introns in ~ 100 genes enriched for nucleocytoplasmic transport
and cell cycle regulators, and caused chromosome segregation
errors. Our findings reveal selectivity in minor intron splicing and
suggest a link between minor spliceosome defects and constitu-
tional aneuploidy in humans.
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Introduction
Chromosome segregation errors in mitosis or meiosis lead to aneu-
ploidy, a karyotype that deviates from an exact multiple of the
haploid set of chromosomes. Aneuploidy is the leading cause of
congenital birth defects and associated with ~ 35% of all sponta-
neous human abortions (Nagaoka et al, 2012). Furthermore,
roughly 70% of human tumors are aneuploid, making it one of the
most common genomic alterations in cancer (Duijf & Benezra, 2013;
Knouse et al, 2017). Despite this common association of aneuploidy
with human disease, little is known about its genetic causes. The
study of aneuploidy-associated hereditary disorders can be instru-
mental in uncovering these causes.
Mosaic variegated aneuploidy (MVA; OMIM: 257300) is a rare
autosomal recessive disorder characterized by mosaic aneuploidies
in multiple tissues. Patients often present with microcephaly, devel-
opmental delay, various congenital abnormalities, and childhood
cancers (Garcıa-Castillo et al, 2008). Pathogenic mutations in
BUB1B, CEP57, or TRIP13, have been identified in roughly half of all
MVA patients (Hanks et al, 2004; Matsuura et al, 2006; Snape et al,
2011; Yost et al, 2017). These genes have well-documented roles in
chromosome segregation (Suijkerbuijk et al, 2010; Sacristan & Kops,
2015; Vader, 2015; Zhou et al, 2016). All three gene products
(BUBR1, CEP57, and TRIP13) promote spindle assembly checkpoint
(SAC) function (Wang et al, 2014; Musacchio, 2015; Ma et al, 2016;
Zhou et al, 2016; Alfieri et al, 2018), and BUBR1 and CEP57 addi-
tionally ensure correct kinetochore–microtubule attachment
(Emanuele & Stukenberg, 2007; Sacristan & Kops, 2015). As
predicted, such mitotic processes are defective in cells from MVA
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patients carrying biallelic mutations in these genes, explaining the
chromosomal instability (CIN) phenotype and resulting aneuploid
karyotypes. CIN can also result from mutations in regulators of
expression of mitotic genes. For example, mutations in the
retinoblastoma gene (RB1) cause CIN by overexpression of the SAC
protein MAD2 (Hernando et al, 2004; Sotillo et al, 2007; Schvartz-
man et al, 2011). In this work, we show that chromosome segrega-
tion errors can be caused by a specific defect in minor intron
splicing, another process governing correct gene expression.
While the conventional, major spliceosome targets most
(> 99.5%) human introns, the minor spliceosome recognizes and
excises only a small subset (~ 700 introns) (Turunen et al, 2013a;
Moyer et al, 2020). These minor introns (also called U12-type
introns) have highly conserved 50 splice site (50ss) and branch point
(BPS) sequences that are longer and differ at the sequence level from
the respective sequences in major (U2-type) introns. Most minor
introns have AT-AC or GT-AG terminal dinucleotides (24 and 69%,
respectively) (Sheth et al, 2006; Moyer et al, 2020). In addition, the
30 terminal nucleotide can vary, thus giving rise to AT-AN and GT-
AN classes of minor introns (Levine & Durbin, 2001; Dietrich et al,
2005). For simplicity, we refer to these as A- and G-type introns,
respectively. Thus far, there has been no indication of mechanistic or
functional differences between the minor intron subtypes.
Minor intron “host” genes, the position of the minor intron
within the gene, and intron subtypes, are all evolutionarily
conserved (Burge et al, 1998; Abril et al, 2005; Sheth et al, 2006;
Alioto, 2007; Moyer et al, 2020). Despite this high conservation, the
functional significance of minor introns has remained elusive.
Elevated levels of unspliced minor introns in various cell types have
been reported, giving rise to the hypothesis that these are rate-
limiting controls for the expression of their host genes (Patel et al,
2002; Younis et al, 2013; Niemel€a & Frilander, 2014; Niemel€a et al,
2014). Nevertheless, the overall significance of the elevated intron
retention (IR) levels has been questioned particularly at individual
gene level (Singh & Padgett, 2009).
The overall architecture of the minor and major spliceosomes is
highly similar. Both are composed of five small ribonucleoprotein
(snRNP) complexes containing small nuclear RNA (snRNA) mole-
cules and a large number of protein components. One of the snRNAs
(U5) is shared between the spliceosomes, while U1, U2, U4, and U6
snRNAs are specific to the major spliceosome, and U11, U12,
U4atac, and U6atac snRNAs to the minor spliceosome. Introns are
initially recognized by the U1 and U2 snRNPs (major spliceosome)
or by the U11/U12 di-snRNP (minor spliceosome), followed by the
entry of the U4/U6.U5 or U4atac/U6atac.U5 tri-snRNP and subse-
quent architectural changes leading to catalytic activation of the
spliceosome (Turunen et al, 2013a). At the protein level, the main
difference between the spliceosomes is in the composition of the
U11/U12 di-snRNP that contains seven unique protein components
that are needed for recognition of the unique minor intron splice
sequences (Will et al, 2004). In contrast, the protein composition of
the minor and major tri-snRNPs appears similar, but rigorous
comparative analyses have been difficult due to the ~ 100-fold lower
cellular abundance of the minor tri-snRNP (Schneider et al, 2002).
Here, we report that germline mutations in a novel component of
the minor spliceosome (CENATAC/CCDC84) cause chromosomal
instability in MVA patients. We identify CENATAC as a minor
spliceosome-specific tri-snRNP subunit that promotes the splicing of
A-type minor introns, but hardly contributes to G-type minor intron
splicing. We show that CENATAC depletion or disease mutations
result in increased A-type minor IR and mitotic chromosome
congression defects. Congression defects are also seen when another
minor spliceosome component is depleted, suggesting that the chro-
mosome segregation errors and aneuploidy observed in MVA
patient cells are secondary effects of defective minor intron splicing.
Results
Biallelic truncating mutations in CENATAC (CCDC84) cause MVA
To search for additional causes of MVA, we performed exome
sequencing and variant analyses on MVA patients and family
members, as previously described (Yost et al, 2017). We identified
biallelic truncating mutations in coiled-coil domain-containing 84
(CCDC84, hereafter named CENATAC, for centrosomal AT-AC splic-
ing factor, see below) in two affected siblings with 7.3 and 8.5%
aneuploid blood cells, respectively (Figs 1A and EV1). Both siblings
were alive at 47 and 33 years of age and had microcephaly, mild
developmental delay, and mild maculopathy. Neither individual had
short stature, dysmorphism, or cancer. Each parent was heterozy-
gous for one of the mutations, and the unaffected sibling had neither
mutation. Moreover, the mutations were absent from the ExAC and
ICR1000 series and we estimated the chance of an individual having
two truncating CENATAC mutations to be 4.8 × 1010 (Fitzgerald
et al, 2015). We therefore consider it very likely that the CENATAC
mutations are the cause of the siblings’ phenotype. The paternal
and maternal mutations (mutation 1 and mutation 2, respectively)
both result in the creation of novel splice sites that lead to a frame-
shift and the loss of the C-terminal 64 amino acids of CENATAC
(Fig 1B and Appendix Fig S1). Although expression of the mutant
alleles was very low in the parental cells, expression of the maternal
allele was elevated in the cells of patient 1 (hereafter called patient)
and was responsible for the low expression of wild-type protein in
these cells due to infrequent recognition of the original splice site
(Fig 1C and Appendix Fig S1C).
CENATAC is an essential gene whose product has previously
been reported to interact with pre-mRNA splicing factors and to
localize to centrosomes where it suppresses centriole over-
duplication and spindle multipolarity (Hart et al, 2015; Wang et al,
2019). Analysis of CENATAC sequence conservation in metazoan
species revealed the presence of two N-terminal C2H2 zinc fingers
and four well-conserved C-terminal sequence motifs, of which the
two most C-terminal ones are lost as a result of the patient muta-
tions (Fig 1B and Appendix Fig S2).
CENATAC promotes error-free chromosome segregation
Live imaging of chromosome segregation in CENATAC mutant
patient lymphoblasts stably expressing H2B-mNeon (Yost et al,
2017) revealed a mild chromosomal instability phenotype, consistent
with the modest levels of aneuploidy in blood cells of these patients
(Figs 1A and 2A). To examine whether CENATAC patient mutations
cause chromosomal instability, we expressed mutant CENATAC alle-
les in HeLa cells in which the endogenous loci were modified to
express AID-degron-tagged CENATAC (HeLaEGFP-AID-CENATAC,
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Appendix Fig S3) (Nishimura et al, 2009). Efficient depletion of
CENATAC through a combination of siRNA treatment and auxin
addition caused chromosome congression defects and a subsequent
mitotic arrest (Fig 2B and C, and Appendix Fig S3). This phenotype
was fully rescued upon re-expression of wild-type but not MVA
mutant CENATAC (Fig 2C and Appendix Figs S4 and S5), indicating
that both MVA mutants are defective for CENATAC’s function in
mitotic chromosome congression. MVA mutant CENATAC caused a
similar mitotic phenotype when expressed in near-diploid DLD-1
cells (Appendix Fig S6). CENATAC alleles missing either of the two
most C-terminal conserved motifs that are absent from MVA mutant
CENATAC (Fig 1B, motifs 3 and 4) did not rescue the mitotic defects.
Instead, the expression of the MVA or motif 3/4 mutants exacerbated
the phenotype, suggesting that these proteins dominantly repressed
the function of any residual wild-type protein (Fig 2C). Mutations in
the zinc fingers or deletion of motifs 1 or 2 only partly compromised
CENATAC function (Figs 1B and 2C).
Live imaging of HeLaEGFP-AID-CENATAC cells with fluorescently
labeled chromatin and microtubules revealed that the chromosome
congression defect upon CENATAC depletion preceded the previ-
ously described loss of spindle bipolarity (Figs 2D and E, and EV2A
and B, Movies EV1 and EV2) (Wang et al, 2019). In addition, we did
not observe centriole over-duplication in CENATAC-depleted cells
(Fig EV2C and D). This is in contrast to what was recently reported
for CENATAC knockout cells (Wang et al, 2019), raising the possibil-
ity that centriole over-duplication is a cumulative effect of prolonged
CENATAC loss. Our attempts to examine this failed, as we were
unable to create CENATAC knockout cells, consistent with it being
an essential human gene (Blomen et al, 2015; Hart et al, 2015; Wang
et al, 2015). Taken together, these data show that CENATAC directly
or indirectly promotes chromosome congression in mitosis (in a
manner likely unrelated to its role in maintaining spindle bipolarity)
and that MVA mutant CENATAC is a defective variant.
CENATAC is a novel component of the minor spliceosome
To investigate in which processes CENATAC plays a role, we
performed a genome-wide, evolutionary co-occurrence analysis.
268
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Case ID 5728_1 (patient 1) 5728_2
Mutation 1 c.805+2_805+19del18 c.805+2_805+19del18
Mutation 2 c.803A>T_p.Glu268Val c.803A>T_p.Glu268Val
Age 47 33
Clinical features:
Mosaic aneuploidies 7,4% 8,5%
Microcephaly Yes Yes
Short stature - -






ZF1 ZF2 Coiled coil M1 M2 M3 M4






















E KSK E KE E KT
I NE WSQK HQ K
NDSQT YMV DKNQHW KGQ YDQHNEAHQTQHPQKKTQMNDRH TQKQSRQNMKDRNHVMWEQNHEAQSRNWL P S FYGRVI W GRKR SRK FYR
Zinc finger 1 (ZF1) Zinc finger 2 (ZF2)



































Figure 1. Biallelic truncating mutations in CENATAC (CCDC84) cause MVA.
A Clinical phenotypes of CENATAC (CCDC84) mutant patients. See also Fig EV1.
B Schematic representation of CENATAC annotated with zinc fingers (ZF1 and ZF2), predicted coiled-coil, and conserved motifs 1–4 (M1–M4). Upper: sequence logos of
both zinc fingers and the conserved residues defining motifs 1–4 (underlined). See Appendix Fig S2 for the full-length logo. Lower: C-terminal protein sequences of
wild-type and MVA mutant CENATAC. The MVA truncation site is indicated by the red dotted line; the four conserved motifs are outlined in red.
C CENATAC and tubulin immunoblots of lysates from lymphoblasts of patient 1 and relatives. Wild-type and truncated, mutant proteins are indicated. Wild-type
CENATAC (CEN): 38 kDa, Mut1: 34.5 kDa (father), Mut2: 31.1 kDa (mother). Phosphorylated CENATAC is indicated with asterisks: black (wild-type), red (Mut1), or blue
(Mut2) (Wang et al, 2019).
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Genes that function in the same biochemical process experience
similar evolutionary pressures and therefore tend to co-evolve, i.e.,
they are lost or retained in a coherent fashion (Pellegrini et al,
1999). Genomes from a set of 90 informative eukaryotic species
(Table EV1) were mined for the presence or absence of CENATAC
orthologs (Hooff et al, 2017). This provided a phylogenetic absence/
presence profile that was used in an unbiased genome-wide query
for genes with similar phylogenetic profiles (Fig 3A). The resulting
list of genes most strongly co-occurring with CENATAC was signifi-
cantly enriched for components of the minor (U12-dependent)
spliceosome complex, including the recently discovered SCNM1
(Bai et al, 2021) (Fig 3B, Table EV2). We thus reasoned that
CENATAC may play a role in splicing by the minor spliceosome.
As predicted by our co-evolution analysis and in agreement with
a previous high-throughput screen (Hart et al, 2015; Hein et al, 2015;
Huttlin et al, 2015, 2017), mass spectrometry analysis of proteins co-
purifying with CENATAC identified several known spliceosome
components that are shared by both the major and minor spliceo-
somes (Fig 3C and Appendix Fig S7). Notably, the strongest
CENATAC interactor (TXNL4B) was also the gene that showed the
most significant co-occurrence with CENATAC in eukaryotic species
(Fig 3A). To determine whether CENATAC preferentially associates
with major or minor spliceosome components, we analyzed
CENATAC co-immunoprecipitations by Northern blot analysis. This
revealed a significant enrichment for the minor spliceosome-specific
U4atac and U6atac snRNAs (Fig 3D and E and Appendix Fig S8).
CENATAC’s association with the minor spliceosome was further
supported by glycerol gradient analyses of HeLa nuclear extract
preparations, which showed co-migration of CENATAC with U6atac
snRNP, U4atac/U6atac di-snRNP, and U4atac/U6atac.U5 tri-snRNP
complexes (Fig 3F). Together, these data validate CENATAC as a
bona fide functional component of the minor spliceosome and as the
first identified protein component that is specific to the U4atac/
U6atac and U4atac/U6atac.U5 snRNP complexes (Fig 3G).
The role of CENATAC in minor spliceosome function was further
supported by the presence of evolutionarily conserved competing
major (U2-type) and minor (U12-type) 50 splice sequences (50ss) in
animals, that are predicted to generate productive and unproductive
CENATAC mRNAs, respectively (Appendix Fig S9A). This configura-















































































































Figure 2. CENATAC promotes error-free chromosome segregation.
A Quantification of chromosome segregation errors of patient and control lymphoblasts expressing H2B-mNeon (four biological replicates, > 200 cells in total per
condition).
B Representative images of H2B-mNeon-expressing HeLaEGFP-AID-CENATAC cells depleted of GAPDH (upper) or CENATAC (middle and lower) with or without re-expression
of CENATAC variants as indicated. IAA, 3-indoleacetic acid. Scale bar, 10 lm.
C Quantification of mitotic defects as in (B) of H2B-mNeon-expressing HeLaEGFP-AID-CENATAC cells treated as indicated (three or five biological replicates, > 85 cells in total
per condition). For 2xZF, the four zinc-finger cysteines were mutated to alanines; for D1–4, the corresponding motif was removed.
D Representative stills of HeLaEGFP-AID-CENATAC cells expressing H2B-mNeon and depleted of CENATAC. Microtubules were visualized with SiR-Tubulin. Arrowheads and
arrows indicate non-congressed chromosomes and supernumerary spindle poles, respectively. Scale bar, 5 lm. Time in hours. See Fig EV2 for the control condition.
See also Movies EV1 and EV2. IAA, 3-indoleacetic acid.
E Quantification of the mitotic phenotype and multipolar spindle formation in time in H2B-mNeon-expressing HeLaEGFP-AID-CENATAC cells treated as in (D) (three
biological replicates, > 44 cells in total per condition). See also Fig EV2.
Data information: In (A, C, E), data are presented as mean  SEM. P-values were calculated with unpaired Student’s t-tests.
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similar to the previously reported autoregulation of the minor
spliceosome proteins 48K and 65K (Verbeeren et al, 2010; Turunen
et al, 2013b). In agreement with this, impaired minor spliceosome
function, such as in Taybi–Linder syndrome (TALS/MOPD1, OMIM:
210710) patients, leads to a significant increase in the use of major
50ss and upregulation of CENATAC mRNA levels (Cologne et al,
2019). Notably, evidence for a similar autoregulatory circuit is also
present in plants (Appendix Fig S9B), where retention or splicing of




































































































Exon 1 Exon 2








































ª 2021 The Authors The EMBO Journal e106536 | 2021 5 of 18
Bas de Wolf et al The EMBO Journal
Minor intron splicing defects in CENATAC mutant cells correlate
with mitotic defects
In agreement with our finding that CENATAC is a novel minor
spliceosome component, splicing of several minor introns was
impaired upon depletion of CENATAC in HeLaEGFP-AID-CENATAC cells,
whereas up- or downstream major introns were unaffected (Fig 4A
and B). This was true also for MVA patient cells and DLD-1 cells
expressing MVA mutant CENATAC (Fig 4B and Appendix Fig S10).
Importantly, the splicing defect of minor introns in CENATAC-
depleted cells was fully rescued by re-expression of wild-type but
not MVA mutant alleles (Fig 4A). Similar to the mitotic phenotype,
the expression of the disease alleles and mutants lacking motifs 3
and 4 exacerbated the splicing defect, whereas mutations in the zinc
fingers and removal of motifs 1 and 2 partially rescued it (Fig 4A
and Appendix Fig S10). Notably, the extent of the splicing defect
strongly correlated with the extent of the mitotic phenotype for all
mutations (Fig 4C), supporting the possibility that impaired minor
spliceosome function and the chromosome congression phenotype
are causally linked. To further investigate this, we depleted ZRSR2,
a component of the U11/U12 di-snRNP functioning in 30ss recogni-
tion of minor introns (see Fig 3G), in both HeLaEGFP-AID-CENATAC and
DLD-1 cells. Similar to the depletion of CENATAC, this caused
significant minor IR (Fig 4D) and a chromosome congression defect
(Fig 4E). We therefore consider it likely that the chromosome
congression phenotype is a secondary effect of impaired minor
spliceosome function.
CENATAC promotes splicing of A-type minor introns
Our discovery of reduced minor spliceosome function in a constitu-
tional aneuploidy syndrome raised the question of which introns
and transcripts were affected by CENATAC malfunction. To investi-
gate this, we compared the transcriptomes of CENATAC-depleted
HeLaEGFP-AID-CENATAC cells to those of control-depleted and parental
cell lines. The resulting RNAseq dataset was analyzed for changes
in IR using IntEREst (Oghabian et al, 2018) and for alternative splic-
ing (AS) using Whippet (Sterne-Weiler et al, 2018). In agreement
with our RT–PCR-based observations (Fig 4), this analysis con-
firmed the significant retention of minor but not major introns after
CENATAC depletion (Fig EV3). Surprisingly, it also uncovered a
remarkable enrichment for a specific subclass of minor introns:
While only 24% of G-type introns (with GT-AG, GT-AT, GT-TG, GC-
AG terminal dinucleotides) were affected by CENATAC depletion,
virtually all (92%) of the A-type introns (with AT-AC1, AT-AA, AT-
AG, or AT-AT terminal dinucleotides) showed increased retention
or activation of alternative major splice sites (cryptic or annotated),
or both (Fig 5A and B, Appendix Fig S11, and Dataset EV1). For
comparison, we carried out the same analysis on a previously
published dataset derived from myelodysplastic syndrome (MDS)
patients carrying somatic mutations in the gene encoding for the
U11/12-di-snRNP subunit ZRSR2 (Madan et al, 2015). This dataset
showed a nearly identical response for A- and G-type introns (Fig 5B
and Dataset EV2). Whereas depletion of CENATAC or mutations
in ZRSR2 led to an average increase of approximately 36 and
19% in retention of A-type introns, respectively (average
DΨCENATAC = ~ 0.36 and average DΨZRSR2 = ~ 0.19), G-type introns
were only strongly affected by ZRSR2 mutations (average
DΨCENATAC = ~ 0.07 and average DΨ ZRSR2 = ~ 0.19, Figs 5B–D and
EV3). Importantly, the effect on A-type introns was specific to minor
introns as none of the 85 major AT-AC introns or related subtypes
responded to CENATAC depletion (Fig 5E and Dataset EV1). The
same subtype-specific effect on minor intron splicing was also
observed in CENATAC mutant MVA patient lymphoblasts (Fig 5F,
Appendix Fig S12A, and Dataset EV3), in which the affected introns
correlated strongly with those affected by CENATAC depletion
(Fig 5G, Appendix Fig S12B, and Dataset EV4). Notably, the
strongly affected transcripts did not include any of the genes associ-
ated with MVA but did contain various mitotic regulators
(Appendix Fig S13, Datasets EV1, EV5, and EV6).
A-type minor introns are spliced less efficiently
We next wished to understand the selectivity of CENATAC-
dependent splicing for A-type minor introns. The observation that
also some G-type introns were affected by CENATAC depletion
(Fig 5D) argued against a direct interaction between CENATAC and
intron terminal nucleotides. Moreover, A- and G-type introns that
were strongly affected by CENATAC depletion had higher basal
levels of IR in control conditions compared with those unaffected by
◀ Figure 3. CENATAC is a novel component of the minor spliceosome.
A Phylogenetic profiles (presences (blue) and absences (white)) of the top 15 genes co-occurring with CENATAC in 90 eukaryotic species. Top: phylogenetic tree of the
eukaryotic species (see Table EV1) with colored areas for the eukaryotic supergroups. 1For NMT1, no human ortholog was found and instead the Arabidopsis
thaliana ortholog is depicted. Genes associated with the minor (U12-dependent) spliceosome are depicted in orange. See also Table EV2.
B GO term analysis of the genes co-occurring with CENATAC as in (A) with a correlation score of > 0.5. Note: The amount of hits and fold enrichment score were
manually changed to accommodate the recently discovered SCNM1 (Bai et al, 2021).
C Graph of fold changes in proteins enriched (P-value < 0.05) in proteomics analysis of CENATAC vs. control co-immunoprecipitations of HeLaEGFP-CENATAC cells (three
biological replicates). Splicing factors are depicted in orange. See also Appendix Fig S7.
D, E Examples (D) and quantification (E) of Northern blot analyses of minor (U6atac, U4atac, U11, and U12) and major (U2, U1, U4, U5, and U6) spliceosome snRNAs in
HeLaEGFP-AID-CENATAC cells (three biological replicates, normalized to the control). See also Appendix Fig S8.
F Glycerol gradient (10–30%) analysis of HeLa S3 nuclear extracts. snRNAs were detected by Northern blot analysis, proteins (CENATAC and PRPF4) by Western blot.
Locations of the U6atac mono-snRNP, U4atac/U6atac di-snRNP, and U4atac/U6atac.U5 tri-snRNP are indicated.
G Schematics showing key assembly stages in minor intron splicing and minor tri-snRNP assembly: intron recognition (A complex) and the catalytic spliceosome (C
complex). For simplicity, several stages of spliceosome assembly are omitted, such as the pre-B complex, which consists of the intron recognition complex together
with the tri-snRNP before architectural changes lead to the exclusion of U11 to give rise to the B complex, after which subsequent architectural changes lead to the
exclusion of U4atac to give rise to the BACT complex, which is a precursor stage for the catalytically active C complex depicted in this figure (Turunen et al, 2013b).
Data information: In (C), data are presented as fold change of the mean log 2-transformed LFQ intensity. In (E), data are presented as mean  SD.
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CENATAC depletion (Fig 6A). This suggested that CENATAC
predominantly promotes splicing of minor introns that are normally
spliced less efficiently and that A-type introns as a group belong to
this category. To test this hypothesis, we engineered the widely used
P120 minigene (Hall & Padgett, 1996) to contain two tandem
competing A- or G-type splice sites in all possible configurations
(Fig 6B). Significantly, minor GT-AG splice sites were strongly
preferred over AT-AC sites when in direct competition (Fig 6B and
C), and they also outcompeted a unique GC-AG splice site that was
significantly affected by CENATAC depletion (Figs 5D and EV4,
LZTR1). We thus conclude that CENATAC promotes splicing of
minor introns that are recognized or spliced less efficiently, most
prominently A-type minor introns.
Discussion
In this work, we have uncovered a novel link between the minor
spliceosome and defects in chromosome segregation in human cells.
Using patient exome sequencing, evolutionary co-occurrence analy-
sis, and biochemistry, we identified CENATAC as a novel protein
component of the U4atac/U6atac di-snRNP and U4atac/U6atac.U5
tri-snRNP complexes that are necessary for the formation of the
catalytically active minor spliceosome. Our RNAseq analyses of
CENATAC-mutant MVA patient cells and CENATAC-depleted
HeLaEGFP-AID-CENATAC cells revealed widespread defects in minor
intron splicing, particularly IR, but also cryptic splice site activation,




























































































































































































Figure 4. Minor intron splicing defects in CENATAC mutant cells fully correlate with mitotic defects.
A RT–PCR (middle panel) and quantification (upper panel) of IPO5 minor intron 21 (U12-type) splicing on RNA extracted from HeLaEGFP-AID-CENATAC cells treated as in
Fig 2C (three biological replicates, normalized to siCENATAC + IAA). The bottom panel shows RT–PCR analysis of IPO5 major intron 19 (U2-type).
B RT–PCRs of IPO5, SUDS3, and ZCCHC8 minor and adjacent major introns on RNA extracted from patient lymphoblasts or HeLaEGFP-AID-CENATAC cells depleted of GAPDH
or CENATAC as indicated. u, unspliced; s, spliced.
C For each condition in (A), minor intron splicing (Fig 4A) was plotted against the percentage of cells showing a mitotic phenotype (Fig 2C). R2 and P-values are
provided for the linear regression trendline (dotted line).
D RT–PCRs of ZRSR2 and GAPDH (to visualize ZRSR2 knockdown efficiency, upper) and RT–PCRs of SUDS3 minor intron 7 (middle) and major intron 5 (lower) on RNA
extracted from HeLaEGFP-AID-CENATAC or DLD-1 cells depleted of GAPDH or ZRSR2 as indicated.
E Quantification of mitotic defects as in Appendix Fig S6 of H2B-mNeon-expressing HeLaEGFP-AID-CENATAC or DLD-1 cells treated as in (D) (three biological replicates, > 103
cells in total per condition).
Data information: In (A, E), data are presented as mean  SEM. P-values were calculated with unpaired Student’s t-tests. In (C), the P and R2 values were calculated with
a linear regression analysis.
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minor spliceosome. Unexpectedly, IR in CENATAC-depleted cells
was strongly biased for A-type minor introns, which is a subtype that
is defined by AT-AN dinucleotide splice sites. This intron subtype-
specific function is unique among the minor spliceosome compo-
nents and correlated tightly with mitotic fidelity. Furthermore,
depletion of the minor spliceosome component ZRSR2 likewise
caused a chromosome congression defect. Minor intron subtype mis-
splicing is therefore likely responsible, possibly in conjunction with
centriolar defects (Wang et al, 2019), for the inefficient chromosome
congression in CENATAC-mutant cells and for the aneuploidies
observed in the two MVA siblings described in this study.
The minor spliceosome was originally thought to splice only
introns with AT-AC termini (Hall & Padgett, 1994, 1996; Tarn &
Steitz, 1996). Only later, it was shown that there are also major AT-
AC introns and that most of the minor introns in fact have GT-AG
termini (Dietrich et al, 1997; Sharp & Burge, 1997; Wu & Krainer,
1997). Additionally, minor introns have infrequent variations in the
30 terminal nucleotide (Levine & Durbin, 2001; Dietrich et al, 2005),
thus giving rise to the AT-AN and GT-AN classes of minor introns,
here referred to as A- and G-type introns, respectively. Significantly,
in all known minor spliceosome diseases for which comprehensive
transcriptome data are available, splicing defects are roughly
uniformly distributed between the A- and G-type introns (Argente
et al, 2014; Madan et al, 2015; Merico et al, 2015; Cologne et al,
2019) (Fig 5A–C, ZRSR2 mutation). The selective A-type IR pheno-
type of CENATAC can therefore not solely be explained by a general
loss of minor spliceosome function but instead suggests that
CENATAC has a unique function in promoting the splicing of A-type
minor introns. Nonetheless, our observation that also a subset of G-
type introns was retained upon CENATAC depletion renders it unli-
kely that CENATAC directly recognizes the 50 adenosine of A-type
introns. Instead, our competition data, and the observed elevated IR
baseline of the affected introns, suggest that a subset of minor
introns with reduced intrinsic splicing activity (consisting not only
of A-type introns but also of a subset of G-type introns) may be
particularly dependent upon CENATAC activity.
What could be the molecular function of CENATAC? Given its
participation in di- and tri-snRNP complexes and potential
selectivity for 50ss identity, CENATAC may function during or after
the transition from initial intron recognition (A complex) to pre-
catalytic spliceosome (B complex; Fig 3G) and may for instance
participate in 50ss recognition analogous to U11-48K protein in the A
complex (Turunen et al, 2008). Of particular interest are the two
well-conserved C-terminal motifs (M3 and M4), whose deletion
caused severe impairment of minor intron splicing (Figs 1 and 4).
Although we have not been able to uncover their function based on
sequence similarity to other motifs, our data argue they are crucial
for CENATAC’s role in minor intron splicing. Detailed mechanistic
understanding will require cryo-EM structures of relevant minor
spliceosome assembly stages. Unlike the major spliceosome, of
which high-resolution structures are available throughout the entire
spliceosome assembly/disassembly cycle (Wilkinson et al, 2020), of
the minor spliceosome only a single high-resolution cryo-EM struc-
ture is available of the catalytically activated form (BACT complex)
(Bai et al, 2021). This structure does not contain CENATAC, nor its
main interactor TXNL4B (Fig 3). Even though the major spliceo-
some does not carry an obvious functional analog of the CENATAC
protein, the major spliceosome TXNL4A/Dim1 protein is a paralog
of TXNL4B, both at sequence and structural levels (Jin et al, 2013).
High-resolution structures of both yeast and human spliceosomal B
complexes have placed TXNL4A/Dim1 in close proximity of the 50ss
and suggested a role in 50ss recognition (Wan et al, 2016; Bertram
et al, 2017). Assuming that the minor spliceosome B complex shares
the molecular architecture with its major spliceosome counterpart,
this could place CENATAC with TXNL4B near the 50ss to participate
in the recognition event. Furthermore, as both proteomics and struc-
tural work have shown that TXNL4A/Dim1 is released from the
major spliceosome during the transition from B to BACT complex
(Schmidt et al, 2014; Bertram et al, 2017; Haselbach et al, 2018), it
is possible that both TXNL4B and CENATAC may similarly detach
from the minor spliceosome prior to BACT complex formation.
Given that A-type minor intron host genes and the locations of
these introns within the host gene are evolutionarily highly
conserved among metazoan species, the selectivity of CENATAC in
splicing raises the possibility that minor intron subtypes are part of
a conserved but unexplored regulatory mechanism for gene
◀ Figure 5. CENATAC promotes splicing of A-type minor introns.
A Sashimi plots showing the effect of CENATAC depletion (48hr, HeLaEGFP-AID-CENATAC cells) or ZRSR2 mutations (MDS patient cells) on AT-AC and GT-AG intron retention
(left panel, Morc3), and cryptic splice site activation (right panel, Tmem231). CENATAC control represents the parental unedited HeLa cell line.
B Transcriptome-wide statistics of CENATAC depletion (48hrs) and ZRSR2 mutations on G- and A-type minor intron retention (U12 IR) and cryptic major splice site
activation (U2 AS). Only introns showing at least 5 exon–exon junctions reads were included. For U12 IR, a statistical cutoff of Padj < 0.05 was used. For U2 AS, the
probability cutoff of Pr > 0.9 was used.
C Density plots showing differences in intron retention (DΨ) distribution after CENATAC depletion (48 h) or in samples with ZRSR2 mutations.
D Hierarchical clustering of A- and G-type intron retention in the unedited parental cell line treated with siGADPH for 48h (column 2), or in the HeLaEGFP-AID-CENATAC cell
line treated with siGADPH for 48h (column 3) or with auxin and siCENATAC for 24 or 48 h (columns 4 and 5, respectively). Only introns showing a Padj < 0.05 and
DΨ > 0.1 in either the 24-h or 48-h depletion sample were included in the analysis. The A-type and G-type intron terminal dinucleotide subtypes are indicated with
different colors in the first column. In case the gene contained multiple introns of the same type, the intron number is indicated in parentheses.
E RT–PCR of major (U2-type) AT-AC introns in SYCP2 (intron 5) and TAF2 (intron 1), and minor (U12-type) AT-AC intron in IPO5 (intron 21) on RNA extracted from
HeLaEGFP-AID-CENATAC cells depleted of GAPDH or CENATAC. Schematic representations of unspliced/spliced PCR products are depicted on the right.
F D_intron_retention values for the MVA patient cell dataset (compared with the healthy sibling) using all (significant and not significant) minor A-type introns
(n = 179 for the depletion and n = 177 for the MVA patient datasets) and minor G-type introns (n = 441 for the depletion and n = 446 for the MVA patient datasets).
Only introns with on average at least 5 intron mapping reads were used in the analysis. See also Appendix Fig S12.
G Venn diagram analysis of the MVA patient cell and HeLaEGFP-AID-CENATAC CENATAC depletion datasets. A- and G-type minor introns showing statistically significant
intron retention in each dataset were used. See also Dataset EV4.
Data information: In (F), data are presented as median (solid line) and mean (dashed line) inside the boxes. The boundaries of the boxes indicate 25th and 75th
percentiles. Whiskers indicate the 90th and 10th percentiles. P-values were calculated with two-sided Mann–Whitney rank-sum tests. The CENATAC depletion dataset
consists of three biological replicates, the ZRSR2 mutation (MDS) dataset of eight biological replicates, and the MVA dataset of four biological replicates.
ª 2021 The Authors The EMBO Journal e106536 | 2021 9 of 18
Bas de Wolf et al The EMBO Journal
expression. CENATAC undergoes reversible modifications (acetyla-
tion and phosphorylation) (Wang et al, 2019), which may provide
the means to regulate its activity (also) in the minor spliceosome.
Presently, all mutations associated with MVA have been mapped
to genes that are known regulators of chromosome segregation. Our
discovery of disease-causing mutations in CENATAC extends this list
for the first time with a mRNA splicing factor. Although a recent
study showed that CENATAC regulates centriole duplication (Wang
et al, 2019), we were unable to verify this. Instead, our data argue
that chromosomal instability by CENATAC malfunction may instead
be the result of a primary defect in splicing of A-type minor introns.
Nevertheless, it remains possible that CENATAC can also promote
high-fidelity chromosome segregation more directly, as has been
suggested for several other proteins involved in splicing (Montem-
bault et al, 2007; Pellacani et al, 2018; Somma et al, 2020).
Strikingly, the clinical phenotype of CENATAC mutant MVA
strongly resembles that of MOPD1/TALS, Roifman and Lowry–
Wood syndromes, which are caused by mutations in the U4atac
snRNA component of the minor spliceosome. Patients with these
syndromes likewise present with microcephaly, developmental
delay, and retinal abnormalities (Farach et al, 2018). No aneuploi-
dies were reported (Hallermayr et al, 2018; Wang et al, 2018), but
karyotype analyses were not performed for the majority of patients.
It will therefore be of interest to examine whether aneuploidies
occur in some of these patients, and whether (and to what extent)
the affected transcripts and the splicing defect differ between MVA
and these syndromes.
Although the depletion of both ZRSR2 and CENATAC caused a
chromosome congression defect in mitosis (Fig 4), patients with
ZRSR2 mutations are clinically different from MVA patients with
CENATAC mutations. This difference is most likely related to dif-
ferences in their splice targets, such as the G-type minor introns that
are differentially affected by depletion of CENATAC vs ZRSR2
(Fig 5). Mutations in ZRSR2 are associated with MDS and clonal
cytopenias of unknown significance (CCUS) (Madan et al, 2015;
Fleischman et al, 2017). In line with ZRSR2’s mitotic phenotype,
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Figure 6. A-type minor introns are spliced less efficiently.
A Density plots showing intron retention (Ψ) values in the HeLa unedited parental control cell line (depleted of GAPDH) of A- and G-type minor introns that were either
unchanged or retained after CENATAC depletion (top) or ZRSR2 mutation (bottom). The median psi values of the retained G- and A-type introns are significantly
higher (Psi = 0.130 and Psi = 0.115, respectively; P < 0.01, Mann–Whitney rank-sum test) compared with the unchanged introns (Psi = 0.081) in the CENATAC
depletion dataset.
B RT–PCR P120 reporter assay (Hall & Padgett, 1996) to measure the relative usage of A-type (AT-AC) and G-type (GT-AG) 50 splice sites in direct competition. Upper:
schematic diagram showing the overall architecture of the reporter construct with its down- and upstream splice site (thick red and blue bars, respectively) and the
products created by splicing (Dn and Up, respectively). Lower: RT–PCRs of the reporter with A- or G-type splice sites in the down- or upstream positions as indicated
below the gel. SS, splice site. *PCR product after use of a cryptic major splice site (not shown in the schematic).
C Quantification of relative splice site usage of A- and G-type splice sites in (B) (three biological replicates).
Data information: In (C), data are presented as mean  SEM. P-values were calculated with unpaired Student’s t-tests. The CENATAC depletion and ZRSR2 mutation
(MDS) datasets (panel (A)) consist of three and eight biological replicates, respectively.
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various stable aneuploidies were observed in MDS and CCUS
patients with ZRSR2 mutations (Madan et al, 2015; Fleischman et al,
2017; Hosono, 2019), though it is unclear whether mitotic defects
contribute to these disease phenotypes. It would be of interest to




The MVA exome analyses were approved by the London Multicen-
tre Research Ethics Committee (05/MRE02/17). Appropriate consent
was obtained from patients and/or parents as applicable and the
experiments conformed to the principles set out in the WMA Decla-
ration of Helsinki and the Department of Health and Human
Services Belmont Report. DNA was extracted from whole blood
using standard protocols. RNA was extracted from EBV-transformed
lymphoblastoid cell lines (LCLs) using the RNeasy Mini Kit protocol
(Qiagen).
For the functional experiments, the following patient LCLs were
used: ID_5728_1 (patient, biallelic CENATAC (CCDC84) mutations,
ECACC ID: FACT5728DLB), ID_5728_3 (sibling, no CENATAC muta-
tions, ECACC ID: FACT5728KC), ID_5728_4 (father, monoallelic
CENATAC mutation, ECACC ID: FACT5728GLB), and ID_5728_5
(mother, monoallelic CENATACmutation, ECACC ID: FACT5728ALB).
Lymphoblastoid cell lines were cultured in RPMI supplemented
with 15% fetal bovine serum (FBS), 100 lg/ml penicillin/strepto-
mycin, and 2 mM alanyl glutamine. Cells expressing H2B-mNeon were
created by lentiviral transduction, using standard procedures. Imaging
of LCLs was performed as previously described (Yost et al, 2017).
Exome sequencing, alignment and variant calling, reference data
sets, PTV prioritization method, recessive analysis, and Sanger
sequencing: as previously described (Yost et al, 2017).
cDNA analysis of CENATAC (CCDC84) mutations
We synthesized cDNA using the ThermoScript RT–PCR System (Life
Technologies) with random hexamers and 1 lg of total RNA. We
amplified the mutation regions using cDNA-specific primers and
sequenced the PCR products as described above. Primer sequences
are available on request.
Conservation logos
Hidden Markov model (HMM) profiles were created from iterative
jackhmmer searches (Potter et al, 2018) (version: HMMER3/f [3.1b2
| January 2014]) with CENATAC’s protein sequence against the
sequences of all metazoan species within the UniProt database. In-
between successive iterations, non-CENATAC sequences were
manually removed. Logos were created using Skylign (Wheeler
et al, 2014); letter height: information content above background.
Immunoblots
For Western blot samples, cells were treated as indicated and lysed
in Laemmli lysis buffer (4% SDS, 120 mM Tris pH 6.8, and 20%
glycerol). Lysates were processed for SDS–polyacrylamide gel elec-
trophoresis and transferred to nitrocellulose membranes.
Immunoblotting was performed using standard protocols. Visualiza-
tion of signals was performed on an Amersham Imager 600 scanner
using enhanced chemiluminescence. Primary antibodies used were
rabbit anti-CENATAC (CCDC84; Sigma, HPA071715) and mouse
anti-Tubulin (Sigma; T5168). Secondary antibodies used were goat
anti-mouse HRP (170-6516) and goat anti-rabbit HRP (170-6515),
both obtained from Bio-Rad.
Cell culture
HeLa T-REx Flp-In osTIR-9Myc::NEO cells (gift from Andrew
Holland) were cultured in DMEM high glucose supplemented with
10% Tet-approved FBS, 100 lg/ml penicillin/streptomycin, and
2 mM alanyl glutamine. DLD-1 cells (ATCC CCL-221) were cultured
in DMEM/F-12 supplemented with 10% Tet-approved FBS, 100 lg/
ml penicillin/streptomycin, and 2 mM alanyl glutamine. HeLa S3
cells (a kind gift from Dr. Joan Steitz) were cultured in suspension
in 1640 RPMI supplemented with 10% FBS, 2 mM glutamine, and
100 lg/ml penicillin/streptomycin. Stable expression of H2B-
mNeon was done by lentiviral transduction using standard proce-
dures. All cell lines were regularly tested and at all times found to
be mycoplasma-free.
Creation of HeLaEGFP-AID-CENATAC and HeLaEGFP -CENATAC cell lines
HeLaEGFP-AID-CENATAC and HeLaEGFP-CENATAC cell lines were derived
from HeLa T-REx Flp-In osTIR-9Myc::NEO and HeLa T-REx Flp-In,
respectively. Tagging of the endogenous locus of CENATAC was
done according to the scCRISPR protocol (Arbab et al, 2015) using
the Protospacer, HDR_insert, and HDR_ext primers in Table EV3.
pcDNA5-FRT-TO-EGFP-AID (Addgene, 80075) was used as template
for both the EGFP-AID and EGFP tags. Cells were transfected with
Lipofectamine LTX using standard procedures and subsequently
FACS-sorted (single cells) based on EGFP expression. Endogenous
tagging was confirmed by PCR (using the Genomic primers,
Appendix Fig S3A) and immunoblotting of CENATAC protein
(Appendix Fig S3B and C).
Viral plasmids, cloning, and viral production
For lentiviral re-expression of CENATAC variants, first pcDNA5
PURO FRT TO EGFP-AID-CENATAC was created by cloning
CENATAC cDNA derived from HeLa cells into empty pcDNA5-FRT-
TO-EGFP-AID (Addgene, 80075) using the cDNA PCR primers in
Table EV3 and digestion of both the PCR product and the plasmid
with NotI/ApaI. The CENATAC cDNA was subsequently cloned into
pcDNA5 PURO FRT TO containing a LAP-tag to create pcDNA5
PURO FRT TO LAP-CENATAC by Gibson assembly (Gibson et al,
2009) with the PCR primers Gibson1 and Gibson2. Mutagenesis was
then performed to make this construct resistant to CENATAC siRNA
treatment (CCDC84; Dharmacon, J-027240-07) by Gibson assembly
with PCR primers Gibson3. Next, in the siRNA-resistant construct,
CENATAC wild-type cDNA was mutated to Mut1 (primers Gibson4),
Mut2 (Gibson5), 2xZF (Gibson6; two consecutive rounds of
cloning), D1 (Gibson7), D2 (Gibson8), D3 (Gibson9), or D4 (Gib-
son10) by Gibson assembly. Lentiviral CENATAC iresRFP constructs
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were derived from a lentiviral construct encoding fluorescently
tagged histone 2B (H2B) and a puromycin-resistant cassette (pLV-
H2B-mNeon-ires-Puro) (Drost et al, 2015). First, the fluorescently
tagged H2B was substituted by CENATAC derived from pcDNA5
PURO FRT TO LAP-CENATAC (see above) by Gibson assembly with
PCR primers Gibson11 and digestion by AscI/NheI. Next, the
puromycin-resistant cassette was substituted by tagRFP by Gibson
assembly with PCR primers Gibson12. Finally, all siRNA-resistant
variants of CENATAC were cloned from their respective pcDNA5
PURO FRT TO LAP-CENATAC plasmids into pLV CENATAC ires-
tagRFP by Gibson assembly with PCR primers Gibson13 and PstI
digestion of the plasmid. Virions were generated by transient trans-
fection of HEK 293T cells with the transfer vector and separate plas-
mids that express Gag-Pol, Rev, Tat, and VSV-G. Supernatants were
clarified by filtration.
Immunoprecipitation
For each sample, a full 10-cm plate of HeLaEGFP-AID-CENATAC cells was
used, treated as indicated (Appendix Fig S3C). The cells were lysed
in ice-cold lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 2% NP-
40, 0.1% deoxycholate, proteasome inhibitors) and treated with
benzonase for 15 min at 4°C. After centrifugation, the supernatant
was incubated with beads (GFP-Trap, Chromotek) for 2.5 h at 4°C
and washed three times with ice-cold lysis buffer. The samples were
finally eluted in Laemmli sample buffer.
Live cell imaging analysis of mitotic fidelity
Lymphoblastoid cell lines were imaged as previously described
(Yost et al, 2017). siRNA transfections (RNAiMAX, Thermo Fisher)
in HeLaEGFP-AID-CENATAC (40 nM siRNA) and DLD-1 cells (50 nM
siRNA) were done against CENATAC (CCDC84; Dharmacon, J-
027240-07), GAPDH (Dharmacon, D-001830-01-05), or ZRSR2
(Sigma, SASI_Hs02_00338940). In the case of CENATAC depletion
in HeLaEGFP-AID-CENATAC cells, transfections were done in the pres-
ence of 1 mM 3-indoleacetic acid (IAA) or ethanol (IAA vehicle) for
24 h in a 24-well plate before the cells were re-plated to eight-well
ibidi l-slides with 2 mM thymidine (for early S-phase synchroniza-
tion) and 100 ll lentivirus for CENATAC re-expression. After 18 h,
the cells were released from thymidine for 6 h and imaged in CO2-
independent medium in a heated chamber (37°C), while air-tight-
sealed in the well plate with parafilm. These cells were therefore
imaged ~ 48 h after siRNA-mediated knockdown of CENATAC and
~ 24 h after lentivirus addition. For CENATAC depletion and re-
expression in DLD-1 cells, the lentivirus (150 ll) was immediately
added together with the siRNA treatment (instead of 24 h later
together with the 2 mM thymidine). These cells were therefore
imaged ~ 48 h after siRNA-mediated knockdown of CENATAC and
~ 48 h after lentivirus addition. For the experiments in Figs 2D and
EV2A, the cells were additionally incubated with 200 nM SiR-
tubulin dye (Spirochrome) for 6 h prior to imaging to facilitate visu-
alization of the mitotic spindle. For the depletion of ZRSR2 in both
HeLaEGFP-AID-CENATAC and DLD-1 cells, the cells were re-plated to 8-
well ibidi l-slides with 2 mM thymidine 48 h (instead of 24 h) after
transfection and therefore imaged ~ 72 h after siRNA-mediated
knockdown of ZRSR2. Images were acquired every 3 or 5 min at
1 × 1 binning in 7 × 2.5 lm z-stacks (RFP as in Appendix Figs S4
and S6 was imaged in only 1 z-stack per position) and projected to a
single layer by maximum intensity projection using NIS-Elements
Software 4.45. Imaging was performed with a Nikon Ti-Eclipse
wide-field microscope equipped with an Andor Zyla 4.2 sCMOS
Camera, 40× oil objective NA 1.3 WD 0.2 mm, and Lumencor
SPECTRA X light engine. Analysis of these experiments was carried
out with ImageJ software. When applicable, cells re-expressing
CENATAC variants were identified through co-expression of cytoso-
lic RFP (via ires-tagRFP); RFP-negative cells were omitted from the
quantifications (Appendix Figs S4 and S6).
Immunofluorescence imaging
After treating the cells with siRNAs and IAA (see above) for 24 h in
a 24-well plate, the cells were re-plated on round 12-mm coverslips
and treated with 2 mM thymidine (for early S-phase synchroniza-
tion) for 24 h. 10 h after release, MG132 was added for 45 min after
which the cells were pre-extracted with 0.1% Triton X-100 in PEM
(100 mM PIPES pH 6.8, 1 mM MgCl2, and 5 mM EGTA) for  60 s.
After 60 s, 4% paraformaldehyde was added on top of the PEM in a
1:1 ratio (400 ll each) for 20 min to fixate the cells. The coverslips
were subsequently washed twice with PBS and blocked with 3%
BSA in PBS for 16 h at 4°C, incubated with primary antibodies for
2 h at room temperature, washed three times with PBS containing
0.1% Triton X-100, and incubated with secondary antibodies for 1 h
at room temperature. Coverslips were then washed four times with
PBS/0.1% Triton X-100 and mounted using ProLong Gold Antifade
with DAPI (Molecular Probes). All images were acquired on a
deconvolution system (DeltaVision Elite; Applied Precision/GE
Healthcare) equipped with a 100×/1.40 NA UPlanSAPO objective
(Olympus) using Softworx 6.0 software (Applied Precision/GE
Healthcare). The images are maximum intensity projections of
deconvoluted stacks. Random pro-metaphase and metaphase cells
were selected, and centrioles were counted by hand. Primary anti-
bodies used were rabbit anti-Centrin1 (Abcam, ab101332, 1/500)
and mouse anti-Tubulin (Sigma, T5168, 1/10,000). Secondary anti-
bodies used were goat anti-mouse 647 (A21236) and goat anti-rabbit
568 (A11036), both obtained from Thermo Fisher.
Co-evolution analysis
First, a phylogenetically diverse set of complete eukaryotic-
predicted proteomes was utilized. This set was previously compiled
to contain the protein sequences of 90 eukaryotic species (Hooff
et al, 2017; preprint: van Wijk & Snel, 2020). These species were
selected based on their representation of eukaryotic diversity. If
available, we selected two species per clade and model organisms
were preferred over other species. If multiple proteomes or
proteomes of different strains were available, the most complete
proteome was selected. When multiple splicing variants of a single
gene were annotated, the longest protein was chosen. A unique
protein identifier was assigned to each protein, consisting of four
letters and six numbers. The letters combine the first letter of the
genus name with the first three letters of the species name. The
versions and sources of the selected proteomes can be found in
Table EV1.
To define phylogenetic profiles for all human proteins, we deter-
mined automatic orthologous groups (OG) across the database using
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information from PANTHER 9.0 (Mi et al, 2016). PANTHER 9.0
contains 85 genomes within total of 1,136,213 genes. Of these
genes, 759,627 genes are in PANTHER families with phylogenetic
trees, multiple sequence alignments, and HMM profiles. In total,
there are 7,180 PANTHER families and 52,768 subfamilies. Families
are groups of evolutionary-related proteins and subfamilies are
related proteins that are likely to have the same function. The divi-
sion into subfamilies is done manually, by biological experts. Every
subfamily of PANTHER is an OG at some taxonomic level in the tree
of life. We used “hmmscan” tool from the HMMER package (Potter
et al, 2018) (HMMER 3.1b1) to find for each protein sequence in our
database, the best matching profile of a main family or subfamily in
PANTHER9.0. The phylogenetic profile of panther main or subfam-
ily was subsequently defined by utilizing the hierarchical nature of
the panther classification. Specifically, the phylogenetic profile of a
main or subfamily also includes all members of daughter families
(and if relevant their daughter families, etc.). Note that due to the
automatic nature of orthology definition and the draft quality of a
few genomes, phylogenetic profiles of the human proteins are not as
accurate as those defined by manual analysis (van Hooff et al,
2019).
To determine the phylogenetic profile similarity, Pearson’s correla-
tion (https://en.wikipedia.org/wiki/Phi_coefficient) was computed
between the phylogenetic profile of the CENATAC panther
(PTHR31198) and the phylogenetic profile of all other panther sub-
and main families using in-house scripts. To detect functional patterns
in orthologous groups with similar phylogenetic profiles (correla-
tion > 0.5), a GO enrichment analysis was performed (Ashburner
et al, 2000; Carbon et al, 2019; Mi et al, 2019). GO cellular component
overrepresentation (GO Ontology database: released 2020-01-03) was
computed using PANTHER (test release 2019-07-11) with the human
reference genome gene set as background. Statistical significance of
overrepresented GO terms was computed using Fisher’s exact test with
FDR correction.
Nuclear extract and GFP pull-down and mass spectrometry
Nuclear extract of wild-type and HeLaEGFP -CENATAC cells was
prepared as described earlier (Kloet et al, 2016). In short, cells were
harvested by trypsinization and resuspended in cold hypotonic
buffer (10 mM HEPES KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl).
Afterward, the cell pellet was homogenized using a Douncer with
type B pestle (tight) to lyse the cell membrane. After centrifuging,
the nuclei were washed with cold PBS and resuspended in cold
buffer for lysis (420 mM NaCl, 20 mM HEPES KOH pH 7.9, 20%
v/v glycerol, 2 mM MgCl2, 0.2 mM EDTA) followed by rotation,
centrifugation, and collection of the nuclear extract. 450 ll of
nuclear extract was used for each GFP pull-down using 15 ll slurry
of GFP-Trap agarose beads (Chromotek), performed in triplicate.
GFP pull-downs were done as described earlier (Smits et al, 2013),
without the addition of EtBr during the incubation, and with an
adapted buffer C (150 mM NaCl, 20 mM HEPES KOH pH 7.9, 20 %
v/v glycerol, 2 mM MgCl2, 0.2 mM EDTA, complete protease inhibi-
tors w/o EDTA, 0.5 mM DTT) for the incubation (+0.1% NP-40)
and washes (+0.5% NP-40). Samples were digested using on-bead
digestion with trypsin overnight (Hubner & Mann, 2011). The tryp-
tic peptides were acidified with TFA and purified on C18 StageTips
(Rappsilber et al, 2007).
After elution from the C18 StageTips, tryptic peptides were sepa-
rated on an Easy-nLC 1000 (Thermo Scientific), connected online to
a Q Exactive HF-X Hybrid Quadrupole-Orbitrap Mass Spectrometer
(Thermo Scientific), using an acetonitrile gradient of 7–30% for
48 min followed by washes of 50–90% acetonitrile, for 60 min of
total data collection. Full scans were measured with a resolution of
120,000, and the top twenty most intense precursor ions were
selected for fragmentation with a resolution of 15,000 and dynamic
exclusion set at 30 s. Peptides were searched against the UniProt
human proteome (downloaded June 2017) using MaxQuant (Cox &
Mann, 2008) (version 1.6.0.1) with default settings, and iBAQ, LFQ,
and match-between-runs enabled. Data analysis was done using
Perseus (version 1.5.5.3), and the volcano plot and stoichiometry
calculations were done as described earlier (Smits et al, 2013) using
in-house-made scripts for R (version 3.6.1).
Nuclear extract preparations for Northern blots
Nuclear extract from HeLa S3 suspension cells was prepared accord-
ing to the protocol described by Dignam et al (1983) using buffer D
containing 50 mM KCL in the final dialysis step.
Immunoprecipitation and Northern blots
100 µl nuclear extract diluted in lysis buffer to a final volume of
200 µl was incubated with 2 µg of anti-CCDC84 antibody (SIGMA-
HPA071715) overnight in the cold room with end-to-end rotation.
The following day capture of antibody–antigen complexes was done
using 50 µl of resuspended Protein G Dynabeads prepared according
to manufacturer’s instructions and incubated with the nuclear
extract antibody samples for 2 h at 4°C. Beads were then washed
four times with lysis buffer lacking protease and RNase inhibitors.
RNA was eluted by proteinase K treatment, extracted once with
phenol:chloroform:isoamyl alcohol (25:24:1; pH 4.8) followed by
ethanol precipitation. RNA was dissolved in H2O or 0.1X TE buffer.
Total volumes of 2 µl (input) and 5 µl (IP) RNA samples were
separated on a 6% polyacrylamide–urea gel and analyzed by North-
ern blotting essentially as described by Tarn and Steitz (1996). Indi-
vidual snRNAs were detected using 32P 50-end-labeled DNA or LNA
oligonucleotides complementary to individual snRNAs. Northern
blots were exposed to image plates and visualized using Typhoon
FLA-9400 Scanner (GE Healthcare, USA) at 50-micron resolution.
The data were quantified using AIDA Software (Raytest, Germany).
Glycerol gradient and ultracentrifugation
HeLa S3 nuclear extracts were preincubated for 0–20 min at +30°C
in a buffer containing 13 mM HEPES (pH 7.9), 2.4 mM MgCl2,
20 mM creatine phosphate, 2 mM DTT, 40 mM KCl, and 0.5 mM
ATP. Aggregates were subsequently removed by a brief centrifuga-
tion (20,000 g, 1 min, +4°C), and the supernatant was subsequently
ultracentrifuged on a linear 10–30% glycerol gradient (20 mM
HEPES, pH 7.9; 40 mM KCl, 2 mM DTT, 2.4 mM MgCl2) for 18 h at
29,000 rpm, +4°C, Sorvall TH641 rotor (RCF(max) = 143,915.6 g).
Following ultracentrifugation, the samples were fractionated. 20%
of each fraction was deproteinized and used for RNA isolation and
Northern blotting and the remaining 80% was subjected to TCA
precipitation, separated on a 10% SDS–PAGE, and analyzed by
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Western blots. Each blot was probed for CENATAC (CCDC84-
HPA071715; Sigma-Aldrich–Merck), PRPF4 (#HPA0221794, Sigma-
Aldrich–Merck).
RT–PCRs
For Figs 4A and 4D, and Appendix Fig S10: Total cellular RNA was
extracted using the RNeasy Kit Protocol (Qiagen) and treated with
DNase I amplification grade (Invitrogen) to remove potential
genomic DNA contamination. cDNA synthesis was carried out using
SuperScriptTM II RT (Thermo Fisher Scientific) and Oligo(dT)18
primers. PCRs were performed with Phusion High-Fidelity DNA
Polymerase (Thermo Fisher Scientific) with the following cycling
conditions: initial denaturation (98°C for 60 s), followed by 28–30
cycles of denaturing (98°C for 10 s), annealing (gene-specific temp.
for 30 s), extension (72°C for 15–20 s), and a final extension (72°C
for 1 min 30 s). PCR primers and relevant annealing temperatures
are listed in Table EV3. PCR products were analyzed on 2% agarose
gel run using 1X TBE buffer. For Figs 4B and 5E, total RNA isolated
was isolated from HeLa cells or patient/control subject lympho-
blasts using TRIzol extraction followed by an additional acidic
phenol (pH 5.0) extraction. 1 µg of RNA was converted to cDNA
using maxima H minus reverse transcriptase (Thermo Fisher)
according to the manufacturer’s protocol. PCRs were performed
essentially as described above, and gene-specific primers and
annealing temperatures are listed in Table EV3.
RNA isolation and high-throughput sequencing
Total RNA isolated was isolated from HeLaEGFP-AID-CENATAC cells
treated with siGAPDH (Dharmacon, D-001830-01-05) for 48 h or
with siCENATAC (CCDC84, Dharmacon, J-027240-07) and 1 mM 3-
indoleacetic acid (IAA) for 24 or 48 h, or unedited HeLa parental
cells treated with siGAPDH for 48 h, or patient/control subject
lymphoblasts using TRIzol extraction followed by an additional
acidic phenol (pH 5.0) extraction. RNAseq libraries were
constructed using Illumina TruSeq Stranded Total RNA Kit (Illu-
mina) Human Ribo-Zero rRNA Depletion Kit (Illumina). Paired-end
150 + 150 bp sequencing was done with Illumina NextSeq 500/550
High Output Kit v2.5 for HeLa samples and with Illumina NovaSeq
6000 using partial S4 flow cell lane for patient samples.
Mapping the reads to the genome
The STAR aligner (Dobin et al, 2013) was used for mapping the
paired sequence reads to the genome (hg38/GRCh38). Transcript
annotations were obtained from GENCODE (v29). The length of
genomic sequence flanking the annotated junctions (sjdbOverhang
parameter) was set to 161. The Illumina adapter sequences
AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC and AGATCGG
AAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGCCGT
ATCATT were, respectively, clipped from the 30 of the first and the
second pairs in the read libraries (using clip3pAdapterSeq parameter).
Differential alternative splicing analysis
Differential AS analysis was done using Whippet (v0.11) (Sterne-
Weiler et al, 2018). Both merged aligned reads (bam files) and AS
event annotations from GENCODE (v29) were used to build the
index reference for AS events. To detect the significantly differential
events, probability cutoff of Pr > 0.9 and percentage spliced in devi-
ation cutoff of |DΨ| > 0.1 were used.
Differential intron retention analysis
For a comprehensive and sensitive IR analysis, the IntEREst R/Biocon-
ductor package was used (Oghabian et al, 2018). After reading binary
alignment (.bam) files, IntEREst detects introns with significantly
higher and lower number of mapped reads relative to the number of
reads that span the introns. The DESeq2-based function of IntEREst,
i.e., deseqInterest(), was used for the differential IR analysis. The
Benjamini–Hochberg method was used for adjusting the P-values, and
a cutoff of Padj < 0.05 was applied to extract the significantly differen-
tial IRs. The reference table was built from the NCBI RefSeq transcrip-
tion annotations based on hg38/GRCh38 genome assembly.
Annotating minor introns
We used IntEREst R/Bioconductor package to annotate the minor
(U12-type) introns as described previously (Oghabian et al, 2018)
using threshold values of 0.07 and 0.14 for 50ss and BPS scores,
respectively. BPS was identified by scanning intronic region from
position 40 to position 3 upstream of the 30ss, and the highest
scoring sequence was selected as the BPS. This list was manually
appended with additional introns that did not fulfill our annotation
criteria (typically because of poor BPS), but have been previously
identified as minor introns (Chang et al, 2007).
P120 minigene cloning, transfection, and analysis of RNA
The double 5´ss constructs were created by insertion mutagenesis
PCR using the P120 minigene (Hall & Padgett, 1996) as a template,
and further modifications of 50 splice sites were made by PCR using
mutagenic primers (for a list of primers used see Table EV3). The
30ss was modified to accommodate for GT-subtype splicing by inser-
tion of a CAG trinucleotide sequence through insertion mutagenesis
PCR. All mutations were confirmed by DNA sequencing. Chinese
hamster ovary cells were transfected with the double 50ss constructs
(1,600 ng per well of a 12-well plate) using Lipofectamine 2000
(Thermo Fisher Scientific), and after 24 h, total RNA was isolated
using TRIzol reagent (Thermo Fisher Scientific). Following DNase
treatment, a pCB6 vector-specific oligonucleotide (ACAGGGATGC
CA) was used for reverse transcription of the RNA with RevertAid
(Thermo Fisher Scientific). RT–PCR was performed with primers
binding exon 6 (GGATGAGGAACCATTTGTGC) and exon 7
(AGAACGAGACCGCCCTTC), and the resulting PCR products were
analyzed on a 3% MetaPhorTM (Lonza) agarose gel. The gel was
imaged using Fuji LAS-3000 CCD Camera, and the band intensities
were quantified using AIDA Software (Raytest, Germany). Identities
of the PCR products were confirmed by DNA sequencing.
Data availability
The authors declare that the data supporting the findings of this
study are available within the paper and its supplementary
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information. The ICR1000 UK exome series data are available at the
European Genome-Phenome Archive (EGA), Reference Number
EGAS00001000971 (https://ega-archive.org/studies/EGAS00001000
971). Exome data for individual patients cannot be made publicly
available for reasons of patient confidentiality. Qualified researchers
may apply for access to these data, pending institutional review
board approval.
HeLaEGFP-AID-CENATAC RNAseq data were deposited in Gene
Expression Omnibus GSE143392 (https://www.ncbi.nlm.nih.gov/ge
o/query/acc.cgi?acc=GSE143392). RNAseq data from the patient
and control subject cannot be made publicly available for reasons of
patient confidentiality. Qualified researchers may apply for access to
these data, pending institutional review board approval.
Protein interaction AP-MS data were deposited in PRIDE
PXD024682 (https://www.ebi.ac.uk/pride/archive/projects/PXD024
682).
Expanded View for this article is available online.
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